Montbrison

Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease often occur together and share similar risk factors. Managing these conditions requires antithrombotic treatments, including anticoagulant therapy (AC) to prevent VTE recurrence and antiplatelet therapy (AP) to prevent major cardiovascular and cerebrovascular events. The combination of AC and AP can increase the risk of side effects, especially bleeding, which is a leading cause of emergency admissions related to adverse drug reactions. This Phase 3 trial compares two treatment strategies in patients with acute VTE who are also taking antiplatelet therapy for atherosclerotic cardiovascular disease. One group receives full-dose anticoagulant therapy alone, while the other group receives combined full-dose anticoagulant therapy plus antiplatelet therapy (aspirin or clopidogrel). The anticoagulant choice is at the investigator's discretion following international guidelines. The study aims to evaluate which strategy better balances the risk of bleeding and cardiovascular events. Participants are monitored for clinically relevant bleeding events during up to 12 months of full-dose treatment. The study also assesses recurrent venous thromboembolism and major adverse ischemic cardiovascular and cerebrovascular events. Throughout the study, researchers collect data on safety and effectiveness to determine the net clinical benefit of each treatment approach. Participation involves regular evaluations and follow-up over the treatment period.